ストックスクリーナーアプリを入手
52.57
0.10%
-0.05
アフターアワーズ：
52.57
前日終値:
$52.62
開ける：
$52.64
24時間の取引高:
5.20M
Relative Volume:
1.66
時価総額：
$2.72B
収益：
$190.41M
当期純損益:
$20.48M
株価収益率:
235.95
EPS:
0.2228
ネットキャッシュフロー:
$46.66M
1週間 パフォーマンス:
-0.06%
1か月 パフォーマンス:
+55.74%
6か月 パフォーマンス:
-22.31%
1年 パフォーマンス:
-25.17%
1日の値動き範囲:
$52.56
$52.68
1週間の範囲:
$52.41
$52.69
52週間の値動き範囲:
$29.43
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
名前
Soleno Therapeutics Inc
セクター
電話
650-213-8444
住所
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
52.57 | 2.72B | 190.41M | 20.48M | 46.66M | 0.2228 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-18 | 開始されました | Wolfe Research | Outperform |
| 2025-10-07 | 開始されました | Goldman | Buy |
| 2025-08-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-23 | 開始されました | TD Cowen | Buy |
| 2025-03-05 | 再開されました | Stifel | Buy |
| 2024-12-02 | 繰り返されました | Robert W. Baird | Outperform |
| 2024-12-02 | 繰り返されました | Stifel | Buy |
| 2024-09-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-10 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-05 | 開始されました | Piper Sandler | Overweight |
| 2024-01-23 | 開始されました | Stifel | Buy |
| 2023-11-21 | 再開されました | Guggenheim | Buy |
| 2020-09-29 | 開始されました | Guggenheim | Buy |
| 2020-01-10 | 開始されました | Craig Hallum | Buy |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2018-02-13 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Soleno Therapeutics Inc (SLNO) 最新ニュース
Halper Sadeh LLC is Investigating Whether MKC, OMEX, SLNO, FORA are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
INVESTOR DEADLINE: Soleno Therapeutics, Inc. (SLNO) Investors with Substantial Losses Have Opportunity to Lead the Soleno Class Action Lawsuit- Hagens Berman - Barchart.com
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure ... - Caledonian Record
SLNO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Conducting Sham Clinical Trials: Levi & Korsinsky - PR Newswire
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application - GlobeNewswire
Soleno Therapeutics stock rallies 56.4% in a week: Here's why - MSN
SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline - TMX Newsfile
SLNO Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Soleno Therapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm - Barchart.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Soleno Therapeutics (SLNO) still appears attractive despite slower US launch ramp projections - MSN
Neurocrine to buy Soleno Therapeutics for $53/share in cash - MSN
Soleno Therapeutics Investors Seek Lead Plaintiff in Class Action - National Today
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman - PR Newswire
Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities - GlobeNewswire
Deadline Alert: Soleno Therapeutics, Inc. (SLNO) - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Soleno - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors - GlobeNewswire
Neurocrine Acquires Soleno for $2.9B - San Diego Business Journal
SLNO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - Sahm
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
SLNO STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Trading the Move, Not the Narrative: (SLNO) Edition - Stock Traders Daily
2026-04-12 | SLNO STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:SLNO | Press Release - Stockhouse
NASDAQ: SLNO: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Soleno Therapeutics, Inc. - NewMediaWire
FinancialContentNASDAQ: SLNO: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Soleno Therapeutics, Inc. - FinancialContent
SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - ACCESS Newswire
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - PR Newswire
Neurocrine Biosciences, Inc. (NBIX) Soleno Therapeutics, Inc.M&A CallSlideshow (NASDAQ:NBIX) 2026-04-10 - Seeking Alpha
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit Investors ... - Bluefield Daily Telegraph
SLNO Shareholder Alert: Soleno Therapeutics, Inc. - GlobeNewswire
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class ActionHagens Berman - Sahm
TD Cowen Downgrades Soleno Therapeutics to 'Hold' - National Today
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Super Micro Computer, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
SLNO DEADLINE NOTICE: Soleno Therapeutics, Inc. Investors Encouraged to Contact Kirby McInerney LLP By May 5, 2026 - ACCESS Newswire
Rosen Law Firm Encourages Soleno Therapeutics Investors to Secure Counsel Before Deadline - National Today
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors with ... - Caledonian Record
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Subst - GuruFocus
SLNO Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
SOLENO LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces - GlobeNewswire
Soleno Therapeutics Investors Seek Lead in Class Action Lawsuit - National Today
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSLNO - PR Newswire
SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein - GlobeNewswire
Soleno Therapeutics Downgraded to 'Hold' by Cantor Fitzgerald - National Today
United StatesGoodwin Advises Centerview And Guggenheim On $2.9 Billion Sale Of Soleno Therapeutics To Neurocrine Biosciences - Mondaq
Soleno Therapeutics Inc (SLNO) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):